CytomX Therapeutics (NASDAQ:CTMX) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

A number of other brokerages have also weighed in on CTMX. Cowen reaffirmed an “outperform” rating on shares of CytomX Therapeutics in a report on Thursday, October 5th. ValuEngine lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Zacks Investment Research raised CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a report on Monday, October 16th. Cantor Fitzgerald assumed coverage on CytomX Therapeutics in a report on Monday, October 23rd. They set an “overweight” rating and a $35.00 price objective on the stock. Finally, Oppenheimer reaffirmed a “hold” rating on shares of CytomX Therapeutics in a report on Wednesday, October 4th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $31.88.

CytomX Therapeutics (NASDAQ CTMX) opened at $21.66 on Friday. CytomX Therapeutics has a twelve month low of $10.40 and a twelve month high of $24.67.

In other CytomX Therapeutics news, major shareholder Robert I. Tepper sold 24,777 shares of the business’s stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $24.34, for a total transaction of $603,072.18. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Debanjan Ray sold 2,500 shares of the business’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $20.58, for a total value of $51,450.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 173,009 shares of company stock worth $3,835,417. 4.70% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of CTMX. Numeric Investors LLC purchased a new stake in CytomX Therapeutics during the second quarter worth $9,730,000. State Street Corp boosted its position in CytomX Therapeutics by 58.8% during the second quarter. State Street Corp now owns 446,315 shares of the biotechnology company’s stock worth $6,914,000 after purchasing an additional 165,342 shares in the last quarter. OxFORD Asset Management LLP boosted its position in CytomX Therapeutics by 425.6% during the third quarter. OxFORD Asset Management LLP now owns 166,079 shares of the biotechnology company’s stock worth $3,001,000 after purchasing an additional 134,484 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of CytomX Therapeutics by 1,063.5% in the second quarter. Goldman Sachs Group Inc. now owns 127,776 shares of the biotechnology company’s stock valued at $1,980,000 after acquiring an additional 116,794 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in shares of CytomX Therapeutics by 185.3% in the third quarter. American Century Companies Inc. now owns 169,799 shares of the biotechnology company’s stock valued at $3,085,000 after acquiring an additional 110,283 shares in the last quarter. Institutional investors own 63.18% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/cytomx-therapeutics-ctmx-stock-rating-upgraded-by-bidaskclub/1764687.html.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.